Sugi Predict

Sugi Predict / Compounds / SCHEMBL899356

SCHEMBL899356

SCHEMBL899356

CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CCC(=O)C(C)(C)C1CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FNTA P49354 2/20 1.00
▸ FNTB P49356 2/20 1.00
▸ MAPT P10636 3/20 0.83
▸ MEN1 O00255 1/20 0.83
▸ PLA2G1B P04054 1/20 0.83
▸ DNMT1 P26358 1/20 0.83
▸ BLM P54132 1/20 0.83
▸ KMT2A Q03164 1/20 0.83
▸ ATG4B Q9Y4P1 1/20 0.83
▸ PTGES O14684 4/20 0.81
▸ PIN1 Q13526 2/20 0.81
▸ PREP P48147 1/20 0.81
▸ CRYAB P02511 2/20 0.74
▸ USP2 O75604 2/20 0.74
▸ ALDH1A1 P00352 2/20 0.74
▸ CYP3A4 P08684 2/20 0.74
▸ ALOX15 P16050 2/20 0.74
▸ LMNA P02545 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17428550 1.00 FNTA (1.00) FNTAFNTBMAPTMEN1PLA2G1B
SCHEMBL2226302 1.00 FNTA (1.00) FNTAFNTBMAPTMEN1PLA2G1B
SCHEMBL29512020 1.00 FNTA (1.00) FNTAFNTBMAPTMEN1PLA2G1B
SCHEMBL20990987 0.92 FNTA (0.84) FNTAFNTBMAPTMEN1PLA2G1B
SCHEMBL18688329 0.92 FNTA (0.84) FNTAFNTBMAPTMEN1PLA2G1B
SCHEMBL15118542 0.92 FNTA (0.84) FNTAFNTBMAPTMEN1PLA2G1B
SCHEMBL18687811 0.92 FNTA (0.84) FNTAFNTBMAPTMEN1PLA2G1B
Anwuweizonic Acid SCHEMBL18687709 0.91 MAPT (1.00) FNTAFNTBMAPTMEN1PLA2G1B
Anwuweizonic Acid SCHEMBL20990961 0.91 MAPT (1.00) FNTAFNTBMAPTMEN1PLA2G1B
Anwuweizonic Acid SCHEMBL12474225 0.91 MAPT (1.00) FNTAFNTBMAPTMEN1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114264756-A Biomarker R1 for diagnosing Parkinson's disease and application thereof 宝枫生物科技（北京）有限公司 2022-04-01 — — CN claimed
CN-114047281-B Combination of biomarkers for parkinson's disease and uses thereof 宝枫生物科技（北京）有限公司 2022-03-25 — — CN claimed
CN-114019079-B Biomarker for diagnosing Parkinson's disease and application thereof 宝枫生物科技（北京）有限公司 2022-03-18 — — CN claimed
CN-114019079-A Biomarker for diagnosing Parkinson's disease and application thereof 宝枫生物科技（北京）有限公司 2022-02-08 — — CN claimed
WO-1996035707-A1 TERPENOID INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-11-14 — — WO claimed
CN-121022946-A Cytochrome P450 oxidase STO1 and encoding gene and application thereof 云南师范大学 2025-11-28 — — CN disclosed
CN-117222731-A Lysine bacillus strain for promoting plant growth and use thereof 国立大学法人东海国立大学机构 2023-12-12 — — CN disclosed
CN-117186053-A Preparation method of lycra ketone intermediate 上海凌凯医药科技有限公司 2023-12-08 — — CN disclosed
CN-117186663-A Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element 日产化学工业株式会社 2023-12-08 — — CN disclosed
CN-116785331-A Application of sweetsop seed extract in preparation of medicine for regulating and controlling biological rhythm 浙江大学 2023-09-22 — — CN disclosed
CN-111240102-B Composition for forming cured film, alignment material, and phase difference material 日产化学工业株式会社 2022-11-15 — — CN disclosed
CN-110167980-B Composition for forming cured film, alignment material, and phase difference material 日产化学株式会社 2022-09-20 — — CN disclosed
WO-2012044817-A2 PROCESS FOR PREPARING DELTA-7,9(11) STEROIDS FROM GANODERMA LUCIDUM AND ANALOGS THEREOF INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2012-04-05 — — WO disclosed
WO-2011088126-A2 TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS EIGER BIOPHARMACEUTICALS, INC. (US) 2011-07-21 — — WO disclosed
US-20080153758-A1 Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease EXONHIT THERAPEUTICS SA (FR) 2008-06-26 — — US disclosed
EP-1811984-A1 COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE Exonhit Therapeutics SA (FR) 2007-08-01 — — EP disclosed
WO-2006051423-A1 COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON’S DISEASE EXONHIT THERAPEUTICS SA (FR) 2006-05-18 — — WO disclosed
EP-1656931-A1 Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease Exonhit Therapeutics SA (FR) 2006-05-17 — — EP disclosed
US-5703067-A USEFUL IN THE TREATMENT OF CANCER MERCK & CO., INC. (US) 1997-12-30 — — US disclosed
WO-1996035707-A1 TERPENOID INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153758-A1 Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease FNTA, GGPS1, FNTB FNTA 1/4885FNTB 3/4885MAPT 596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.